Yahoo Web Search

Search results

1. • (ABBV) - Analyzing AbbVie's Short Interest - AbbVie (NYSE:ABBV)

     Benzinga· 10 hours ago

     AbbVie's ABBV short percent of float has risen 4.05% since its last report. Based on its trading volume, it would take traders 2.43 days to cover their short positions on ...

2. • 

     3 Rock-Solid Dividend Stocks That Are Ideal for Retirees

     Motley Fool via Yahoo Finance· 16 hours ago

     Three stocks that you'll want to consider for your portfolio if you're a retiree craving some...

3. • 

     AbbVie Stock Poised for New All-Time Highs in 2024 | Investing.com

     Investing.com· 3 days ago

     AbbVie had a better-than-expected quarter and guided higher; the post-release price drop is a dip...

4. • 

     3 Reasons to Buy AbbVie Stock on the Dip

     Motley Fool via Yahoo Finance· 5 days ago

     It's been more than a year since AbbVie (NYSE: ABBV) lost patent exclusivity for its most important product, Humira, an immunology medicine. Though this...

5. • AbbVie to Present at the Bank of America Securities Healthcare Conference

     FOX 4 Kansas City· 5 days ago

     Reents, executive vice president, chief financial officer, Jeffrey R. Stewart, executive vice president, chief commercial officer and Roopal Thakkar, M.D., senior vice president, chief medical ...

6. • Keeping an Eye on Abbvie Inc

     Knox Daily· 4 days ago

     Abbvie Inc’s recently made public that its EVP, CHIEF BUS/STRAT OFFICER Donoghoe Nicholas unloaded Company’s shares for reported $3.72 million on Mar 20 ’24. In the deal valued ...

7. • ABBV34 | AbbVie Inc Share Price - Investing.com NG

     Investing.com· 5 days ago

     Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for ...

8. • Ironwood (IRWD) Q1 Earnings & Revenues Fall Shy of Estimates

     Zacks· 1 day ago

     The top line decreased almost 28% year over year due to a $30.0 million gross-to-net change in estimate for the sole marketed drug, Linzess (linaclotide), recorded to collaborative arrangements ...

9. • 

     Regenxbio Inc (RGNX) Q1 2024 Earnings: Misses Analyst Revenue and EPS Forecasts

     GuruFocus.com via Yahoo Finance· 11 hours ago

     The company's ongoing collaborations, like those with AbbVie on ABBV-RGX-314 for retinal diseases,...

10. • 

      Merck and other pharma giants are bracing for competition to their blockbuster drugs. Here's how.

      Quartz· 3 days ago

      Every pharmaceutical company is constantly searching for its next blockbuster — the billion-dollar...